Armata Pharmaceuticals Inc
AMEX:ARMP
ARMP's latest stock split occurred on May 10, 2019
The company executed a 1-for-14 stock split, meaning that for every 14 shares held, investors received 1 new share.
Before the split, ARMP traded at 0.3179 per share. Afterward, the share price was about 4.65.
The adjusted shares began trading on May 10, 2019. This was ARMP's 4th stock split, following the previous one in Apr 25, 2017.
COKE
300791
ALV
Armata Pharmaceuticals Inc
Glance View
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Marina Del Rey, California and currently employs 72 full-time employees. The firm is focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The company has developed care therapies, including the multidrug-resistant or superbug strains of bacteria. The firm is a developer of phage therapeutics, which are positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections. The company is developing and advancing its lead clinical phage candidate for Pseudomonas aeruginosa. The firm is also developing a phage product candidate for Staphylococcus aureus for the treatment of staphylococcus aureus bacteremia. The company has phage development to target other indications, including non-cystic fibrosis bronchiectasis, prosthetic joint infections and hospitalized pneumonia. Its product candidates are AP-PA02, AP-PA03 and AP-SA02.
You don't have any saved screeners yet